A well-capitalized strategic investor looking to enter the radiopharmaceuticals market wanted to conduct clinical due diligence on a novel radioisotope-conjugated antibody designed to treat solid tumors.
We assessed the clinical performance of the product, putting it into the context of cancer therapies in general and benchmarked it against other competing therapies designed to treat the same cancer. We considered whether the product was sufficiently differentiated from its peers, in addition to its likely commercial potential.
We concluded that the clinical trials conducted to date were largely academic and had been performed in a broad range of patient groups. There was little clinical experience in the target patient population of the intended Phase III and in our view an investment in a Phase III program was not justified.
Alacrita's due diligence consultants have been a trusted source of pharma and biotech DD for over 15 years, underpinned by our ability to ensure each due diligence exercise is supported by individuals with the precise industry expertise required to be thorough, complete and accurate.